DAXOR CORP (DXR) Stock News

USA - Nasdaq - NASDAQ:DXR - US2394671034 - Common Stock

13.3 USD

+0.2 (+1.53%)

Last: 11/28/2025, 8:24:47 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DXR Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Daxor Corporation

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

2 months ago - By: Daxor Corporation

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

2 months ago - By: Daxor Corporation

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

4 months ago - By: Daxor Corporation

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

7 months ago - By: Daxor Corporation

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

7 months ago - By: Daxor Corporation

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

8 months ago - By: Daxor Corporation

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

8 months ago - By: Daxor Corporation

Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

8 months ago - By: Daxor Corporation

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo

8 months ago - By: Daxor Corporation

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

9 months ago - By: Daxor Corporation

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

9 months ago - By: Daxor Corporation

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

9 months ago - By: Daxor Corporation

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

9 months ago - By: Daxor Corporation

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

9 months ago - By: Daxor Corporation

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

9 months ago - By: Daxor Corporation

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

9 months ago - By: Daxor Corporation

Daxor to Exhibit at World's Largest Critical Care Conference

10 months ago - By: Daxor Corporation

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

10 months ago - By: Daxor Corporation

New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care

a year ago - By: Daxor Corporation

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

a year ago - By: Daxor Corporation

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

a year ago - By: Daxor Corporation

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

a year ago - By: Daxor Corporation

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

a year ago - By: Daxor Corporation

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

a year ago - By: Daxor Corporation

Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

a year ago - By: Daxor Corporation

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

a year ago - By: Daxor Corporation

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Daxor Corporation

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

a year ago - By: Daxor Corporation

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

a year ago - By: Daxor Corporation

Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer

a year ago - By: Daxor Corporation

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

1 years ago - By: Daxor Corporation

Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

2 years ago - By: Daxor Corporation

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

2 years ago - By: Daxor Corporation

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

2 years ago - By: Daxor Corporation

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

2 years ago - By: Daxor Corporation

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

2 years ago - By: Daxor Corporation

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

2 years ago - By: Daxor Corporation

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

2 years ago - By: Daxor Corporation

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

2 years ago - By: Daxor Corporation

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference